Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based pharmaceutical firm Mylan has introduced Potassium Chloride Extended-release Tablets USP, 8mEq (600mg) and 10mEq (750mg), which is the generic version of Upsher-Smith's Klor-Con.
Subscribe to our email newsletter
The company has also secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product.
The product is indicated to treat patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis.
According to IMS Health, Potassium Chloride Extended-release Tablets USP, 8 mEq (600mg) and 10 mEq (750 mg), had US sales of about $135.05m for the 12 months ending 30 June 2014.
At present, the company has 294 ANDAs pending FDA approval representing $105.7bn in annual brand sales.
According to the company, 43 of these pending ANDAs are potential first-to-file opportunities, representing $25bn in annual brand sales, for the 12 months ending 31 December 2013.
Mylan offers a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications.
Additionally, the company provides a wide range of antiretroviral therapies, upon which about 40% of HIV/AIDS patients in developing countries depend.
The company also operates one of the largest active pharmaceutical ingredient manufacturers and currently markets products in about 140 countries and territories.